Beta-Blocker Therapy Post-MI: Evidence and Recommendations
Early initiation of oral beta-blockers within 24 hours is strongly recommended for all ACS patients without contraindications, but long-term continuation beyond hospital discharge should be reserved primarily for patients with reduced LVEF (<40%) or heart failure, as recent high-quality evidence shows no mortality benefit in those with preserved ejection fraction. 1, 2
Early Initiation (First 24 Hours)
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide a Class 1 recommendation for early oral beta-blocker therapy in ACS patients without contraindications 1, 2. This recommendation aims to:
- Reduce risk of reinfarction
- Prevent ventricular arrhythmias
- Decrease myocardial oxygen demand through reduced heart rate, blood pressure, and contractility
Key Implementation Points:
Start with LOW doses orally and escalate slowly as blood pressure and heart rate permit. The COMMIT trial demonstrated that high-dose IV metoprolol (up to 15 mg IV then 200 mg oral daily) increased cardiogenic shock risk, particularly in the first 24 hours 2.
Absolute Contraindications to Early Beta-Blocker Initiation:
- Acute heart failure (Killip class II-IV)
- Evidence of low cardiac output state or cardiogenic shock risk
- PR interval >0.24 milliseconds
- Second- or third-degree heart block without pacemaker
- Severe bradycardia
- Active bronchospasm
Critical caveat: Patients with initial contraindications should be reassessed after 24 hours and started on therapy if contraindications have resolved 1, 2.
Long-Term Therapy: The Evidence Has Changed
For Patients with LVEF ≥40% (Preserved or Mildly Reduced):
The evidence landscape shifted dramatically in 2025 with two large, contemporary randomized trials that challenge decades of practice:
The BETAMI-DANBLOCK trial (2025,5,574 patients, median 3.5 years follow-up) showed a modest reduction in the composite primary endpoint (HR 0.85,95% CI 0.75-0.98, p=0.03), driven primarily by reduced reinfarction (HR 0.73,95% CI 0.59-0.92), but no mortality benefit (4.2% vs 4.4%) 3.
The REBOOT trial (2025,8,438 patients, median 3.7 years follow-up) found no benefit whatsoever for beta-blockers in preserved LVEF patients (HR 1.04,95% CI 0.89-1.22, p=0.63), with no differences in death, reinfarction, or heart failure hospitalization 4.
A 2025 meta-analysis of 19,826 patients from four RCTs confirmed no significant benefit for the primary composite outcome (HR 0.93,95% CI 0.82-1.04) in patients with LVEF ≥40% 5.
Critical Subgroup Finding:
Patients with mildly reduced LVEF (40-49%) may derive benefit (RR 0.76,95% CI 0.61-0.94), while those with preserved LVEF (≥50%) clearly do not (RR 0.96,95% CI 0.86-1.08) 6. This suggests a gradient of benefit that disappears as LVEF improves.
For Patients with LVEF <40% or Heart Failure:
The benefit remains well-established and unquestioned 1, 2. These patients should receive indefinite beta-blocker therapy as it reduces mortality and morbidity.
Practical Algorithm for Beta-Blocker Management Post-MI
At Hospital Presentation (Day 0-1):
- Assess for contraindications (see list above)
- If no contraindications: Start LOW-dose oral beta-blocker within 24 hours
- If contraindications present: Reassess at 24 hours and initiate if resolved
Before Hospital Discharge:
- Obtain LVEF measurement (echocardiography)
- Assess for heart failure symptoms/signs
Discharge Planning Decision Tree:
LVEF <40% OR clinical heart failure present:
- Continue beta-blocker indefinitely (Class 1 indication)
- Target evidence-based doses (e.g., carvedilol 25 mg BID, metoprolol succinate 200 mg daily)
LVEF 40-49% (mildly reduced):
- Consider continuation based on individual risk factors
- Reasonable to continue given subgroup benefit 6
- Discuss risks/benefits with patient
LVEF ≥50% (preserved) AND no heart failure:
- Beta-blocker continuation is NOT necessary based on contemporary evidence
- Can safely discontinue or withhold at discharge 4, 7
- No increased short-term or long-term ischemic risk with withdrawal 7
Important Caveats
The guideline recommendations 1, 2 were written before the full publication of the 2025 REBOOT and BETAMI-DANBLOCK trials, and while they acknowledge uncertainty about long-term benefit in preserved LVEF patients, they do not yet incorporate the definitive negative findings from these large contemporary trials.
Safety of withdrawal: The REBOOT post-hoc analysis specifically demonstrated that withdrawing beta-blockers in patients who were on them chronically before MI did not increase ischemic events (HR 0.93,95% CI 0.64-1.34) 7.
Most RCT data for early use comes from the pre-reperfusion era, and no adequately powered trials have examined early beta-blocker benefit specifically in NSTE-ACS patients 1, 2.